0.32
+1.92%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Biovica International
Its shares trade on Nasdaq Stockholm under the ticker BIOVIC B.ST. It has been listed since 29 March 2017. In the fiscal year to 30 April 2026, it reported revenue of SEK 13.4m and a net loss of SEK 69.9m. At that date it held total assets of SEK 107.7m and shareholders' equity of SEK 86.3m.
Biovica International AB is engages in the development and commercialization of novel blood-based biomarker assays to improve the monitoring of modern cancer therapies. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2017-03-29. The company develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The firm has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The firm collaborates with numerous institutions, such as Karolinska Institutet in Sweden and Dana Farber Cancer Institute, Washington University, Baylor College of Medicine, City of Hope Research & Treatment Center in the Unites States, as well as The International Breast Cancer Study Group (IBCSG) based in Switzerland and Breast International Group in Belgium.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 29 Mar 2017
- Employees
- 17
- Website
- biovica.com ↗
Leadership
Pay as last reported
- Mr. Fredrik AlpstenIndependent Chairman of the Board
- Mr. Anders RylanderChief Executive Officer, Director, since 2010SEK 1.1m
- Mr. Anders MorenChief Financial Officer
- Mr. Henrik WintherSenior Vice President - Business Development
- Ms. Helle FiskerVice President - Commercial and MarketingSEK 75,000
- Ms. Hanna RitzenVice President - Research & Development
- Mr. Hector TamburiniHead of US Laboratory Operations, Regulatory & Quality
- Ms. Annika BergIndependent DirectorSEK 200,000
- Mr. Cornelis BogerdIndependent Director
- Dr. Marie-Louise FjallskogIndependent DirectorSEK 300,000
- Ms. Maria HolmlundIndependent DirectorSEK 275,000
- Mr. Jesper SoderqvistIndependent DirectorSEK 275,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 34
- Environment
- 38
- Social
- 27
- Governance
- 36
- Women in the workforce
- 55%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Biovica International AB possesses a unique and innovative technology that enables the identification and measurement of certain biomarkers in blood samples. This technology sets the company apart from its competitors and provides a strong foundation for its products and services.
- The company owns a significant number of patents and intellectual property rights related to its technology and products. This portfolio acts as a barrier to entry for competitors and provides Biovica with a competitive advantage.
Weaknesses
- Biovica International AB relies heavily on strategic partnerships for the development, manufacturing, and distribution of its products. This reliance may pose risks in terms of maintaining control over the value chain and potential conflicts of interest.
- The company's market presence is relatively limited compared to established competitors. This may result in challenges in terms of market penetration, brand recognition, and customer acquisition.
Opportunities
- The increasing focus on personalized medicine presents a significant opportunity for Biovica International AB. Its technology can contribute to improving treatment decision-making by providing valuable insights into patients' individual characteristics and disease progression.
- The company has the potential to expand its operations into new geographies, where there is a demand for its products and services. This expansion can help Biovica increase its market share and revenue streams.
Threats
- Biovica operates in a highly competitive market, facing competition from both established players and emerging startups. This intense competition may impact the company's ability to gain market share and maintain pricing power.
- Adherence to regulatory requirements and obtaining necessary approvals for the company's products can be complex and time-consuming. Failure to comply with regulations or delays in approvals may hinder Biovica's ability to bring products to market and generate revenue.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.